Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.92
HZNP's Cash to Debt is ranked higher than
59% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. HZNP: 0.92 )
HZNP' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.92

Equity to Asset -0.77
HZNP's Equity to Asset is ranked lower than
59% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. HZNP: -0.77 )
HZNP' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.7
Current: -0.77

-0.77
0.7
F-Score: 3
Z-Score: -5.25
M-Score: 0.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -57.90
HZNP's Operating margin (%) is ranked lower than
51% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. HZNP: -57.90 )
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5   Max: -57.9
Current: -57.9

-1841.5
-57.9
Net-margin (%) -201.31
HZNP's Net-margin (%) is ranked lower than
54% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. HZNP: -201.31 )
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12   Max: -201.31
Current: -201.31

-1635.12
-201.31
ROA (%) -58.99
HZNP's ROA (%) is ranked lower than
55% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. HZNP: -58.99 )
HZNP' s 10-Year ROA (%) Range
Min: -249.6   Max: -16.74
Current: -58.99

-249.6
-16.74
ROC (Joel Greenblatt) (%) -1133.70
HZNP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. HZNP: -1133.70 )
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7948.82   Max: -1133.7
Current: -1133.7

-7948.82
-1133.7
Revenue Growth (%) -14.60
HZNP's Revenue Growth (%) is ranked higher than
50% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. HZNP: -14.60 )
HZNP' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -14.6
Current: -14.6

EBITDA Growth (%) -74.50
HZNP's EBITDA Growth (%) is ranked lower than
56% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. HZNP: -74.50 )
HZNP' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -74.5
Current: -74.5

EPS Growth (%) -52.00
HZNP's EPS Growth (%) is ranked lower than
51% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. HZNP: -52.00 )
HZNP' s 10-Year EPS Growth (%) Range
Min: 0   Max: -52
Current: -52

» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

HZNP Guru Trades in Q3 2012

Columbia Wanger 1,290,000 sh (-7.53%)
» More
Q4 2012

HZNP Guru Trades in Q4 2012

Columbia Wanger Sold Out
» More
Q4 2013

HZNP Guru Trades in Q4 2013

Jim Simons 358,000 sh (New)
Paul Tudor Jones 14,646 sh (New)
» More
Q1 2014

HZNP Guru Trades in Q1 2014

Paul Tudor Jones 16,733 sh (+14.25%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HZNP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 4.58
HZNP's P/S is ranked higher than
58% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. HZNP: 4.58 )
HZNP' s 10-Year P/S Range
Min: 1.47   Max: 19.46
Current: 4.58

1.47
19.46
EV-to-EBIT -30.65
HZNP's EV-to-EBIT is ranked lower than
54% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. HZNP: -30.65 )
HZNP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -30.65

Current Ratio 2.34
HZNP's Current Ratio is ranked higher than
70% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. HZNP: 2.34 )
HZNP' s 10-Year Current Ratio Range
Min: 0.16   Max: 4.39
Current: 2.34

0.16
4.39
Quick Ratio 2.21
HZNP's Quick Ratio is ranked higher than
75% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. HZNP: 2.21 )
HZNP' s 10-Year Quick Ratio Range
Min: 0.16   Max: 4.27
Current: 2.21

0.16
4.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
HZNP's Price/Median PS Value is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. HZNP: 1.00 )
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 3.73
Current: 1

0.37
3.73

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPM.Germany
Horizon Pharma Inc is a specialty pharmaceutical company. It has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide